Header Logo

Connection

Lawrence Kushi to Antineoplastic Agents, Hormonal

Back to Details
This is a "connection" page, showing publications Lawrence Kushi has written about Antineoplastic Agents, Hormonal.
Lawrence Kushi
Connection Strength
1.121
Antineoplastic Agents, Hormonal
  1. Adjuvant endocrine therapy for breast cancer patients: impact of a health system outreach program to improve adherence. Breast Cancer Res Treat. 2020 Feb; 180(1):219-226.
    View in: PubMed
    Score: 0.168
  2. Personal and clinical social support and adherence to adjuvant endocrine therapy among hormone receptor-positive breast cancer patients in an integrated health care system. Breast Cancer Res Treat. 2018 Aug; 170(3):623-631.
    View in: PubMed
    Score: 0.149
  3. Changes in bone mineral density in women with breast cancer receiving aromatase inhibitor therapy. Breast Cancer Res Treat. 2018 Apr; 168(2):523-530.
    View in: PubMed
    Score: 0.146
  4. Patterns and reasons for switching classes of hormonal therapy among women with early-stage breast cancer. Cancer Causes Control. 2017 Jun; 28(6):557-562.
    View in: PubMed
    Score: 0.138
  5. Non-initiation of adjuvant hormonal therapy in women with hormone receptor-positive breast cancer: The Breast Cancer Quality of Care Study (BQUAL). Breast Cancer Res Treat. 2012 Jul; 134(1):419-28.
    View in: PubMed
    Score: 0.098
  6. Racial/ethnic differences in initiation of adjuvant hormonal therapy among women with hormone receptor-positive breast cancer. Breast Cancer Res Treat. 2012 Jan; 131(2):607-17.
    View in: PubMed
    Score: 0.094
  7. Early discontinuation and non-adherence to adjuvant hormonal therapy are associated with increased mortality in women with breast cancer. Breast Cancer Res Treat. 2011 Apr; 126(2):529-37.
    View in: PubMed
    Score: 0.088
  8. Early discontinuation and nonadherence to adjuvant hormonal therapy in a cohort of 8,769 early-stage breast cancer patients. J Clin Oncol. 2010 Sep 20; 28(27):4120-8.
    View in: PubMed
    Score: 0.087
  9. Development of cardiometabolic risk factors following endocrine therapy in women with breast cancer. Breast Cancer Res Treat. 2023 Aug; 201(1):117-126.
    View in: PubMed
    Score: 0.053
  10. Serum bone markers and risk of osteoporosis and fragility fractures in women who received endocrine therapy for breast cancer: a prospective study. Breast Cancer Res Treat. 2020 Feb; 180(1):187-195.
    View in: PubMed
    Score: 0.042
  11. Psychosocial factors related to non-persistence with adjuvant endocrine therapy among women with breast cancer: the Breast Cancer Quality of Care Study (BQUAL). Breast Cancer Res Treat. 2016 05; 157(1):133-43.
    View in: PubMed
    Score: 0.032
  12. The Breast Cancer Quality of Care Study (BQUAL): a multi-center study to determine causes for noncompliance with breast cancer adjuvant therapy. Breast J. 2012 May-Jun; 18(3):203-13.
    View in: PubMed
    Score: 0.025

© 2025 Kaiser Permanente